Celcuity Inc. (NASDAQ:CELC) Stake Lowered by AlphaQuest LLC

AlphaQuest LLC cut its stake in shares of Celcuity Inc. (NASDAQ:CELC) by 58.4% in the 4th quarter, Holdings Channel reports. The firm owned 7,894 shares of the company’s stock after selling 11,068 shares during the quarter. AlphaQuest LLC’s holdings in Celcuity were worth $103,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently made changes to their positions in the stock. State Street Corp grew its holdings in shares of Celcuity by 152.2% during the third quarter. State Street Corp now owns 1,107,415 shares of the company’s stock valued at $16,512,000 after purchasing an additional 668,318 shares during the last quarter. Braidwell LP grew its holdings in Celcuity by 71.2% in the 3rd quarter. Braidwell LP now owns 884,306 shares of the company’s stock worth $13,185,000 after buying an additional 367,663 shares in the last quarter. Geode Capital Management LLC grew its holdings in Celcuity by 27.6% in the 3rd quarter. Geode Capital Management LLC now owns 630,369 shares of the company’s stock worth $9,401,000 after buying an additional 136,518 shares in the last quarter. Candriam S.C.A. bought a new position in Celcuity in the 4th quarter worth approximately $3,450,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in Celcuity by 7.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 237,706 shares of the company’s stock worth $3,112,000 after buying an additional 16,035 shares in the last quarter. 63.33% of the stock is owned by institutional investors.

Celcuity Stock Performance

Shares of NASDAQ CELC opened at $10.09 on Wednesday. The stock has a fifty day moving average price of $11.36 and a two-hundred day moving average price of $13.23. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35. The firm has a market cap of $374.64 million, a P/E ratio of -3.87 and a beta of 0.65. Celcuity Inc. has a 1 year low of $8.53 and a 1 year high of $22.19.

Analyst Ratings Changes

Separately, Needham & Company LLC increased their price objective on Celcuity from $23.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Celcuity presently has a consensus rating of “Buy” and a consensus price target of $30.17.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.